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BACKGROUND: Defective DNA repair has a causal role in hereditary colorectal cancer (CRC). Defects in the base excision repair gene
MUTYH are responsible for MUTYH-associated polyposis and CRC predisposition as an autosomal recessive trait. Numerous reports
have suggested MUTYH mono-allelic variants to be low penetrance risk alleles. We report a large collaborative meta-analysis to assess
and refine CRC risk estimates associated with bi-allelic and mono-allelic MUTYH variants and investigate age and sex influence on risk.
METHODS: MUTYH genotype data were included from 20 565 cases and 15 524 controls. Three logistic regression models were tested:
a crude model; adjusted for age and sex; adjusted for age, sex and study.
RESULTS: All three models produced very similar results. MUTYH bi-allelic carriers demonstrated a 28-fold increase in risk (95%
confidence interval (CI): 6.95–115). Significant bi-allelic effects were also observed for G396D and Y179C/G396D compound
heterozygotes and a marginal mono-allelic effect for variant Y179C (odds ratio (OR)¼ 1.34; 95% CI: 1.00–1.80). A pooled meta-
analysis of all published and unpublished datasets submitted showed bi-allelic effects for MUTYH, G396D and Y179C (OR¼ 10.8,
95% CI: 5.02–23.2; OR¼ 6.47, 95% CI: 2.33–18.0; OR¼ 3.35, 95% CI: 1.14–9.89) and marginal mono-allelic effect for variants
MUTYH (OR¼ 1.16, 95% CI: 1.00–1.34) and Y179C alone (OR¼ 1.34, 95% CI: 1.01–1.77).
CONCLUSIONS: Overall, this large study refines estimates of disease risk associated with mono-allelic and bi-allelic MUTYH carriers.
British Journal of Cancer (2010) 103, 1875–1884. doi:10.1038/sj.bjc.6605966 www.bjcancer.com
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Oxidative damage to DNA occurs with cell proliferation and
increases with age. Certain organs such as the gut are heavily
exposed to oxidising agents, which impacts on carcinogenic
potential. Dysfunction of base excision repair, the major pathway
for repairing oxidative damage, has been implicated as a risk factor
for the development of multiple colorectal adenomas and colo-
rectal cancer (CRC; Al-Tassan et al, 2002; Croitoru et al, 2004;
Farrington et al, 2005). Bi-allelic mutations of the MUTYH gene
seem to be responsible for a high proportion of the multiple
adenoma phenotype families (termed MUTYH-associated poly-
posis (MAP)) unaccounted for by germline APC mutations
(Al-Tassan et al, 2002; Sampson et al, 2003; Sieber et al,
2003; Gismondi et al, 2004; Venesio et al, 2004; Nielsen et al,
2009) and predispose to CRC per se (Enholm et al, 2003;
Croitoru et al, 2004; Fleischmann et al, 2004; Kambara et al,
2004; Wang et al, 2004; Farrington et al, 2005; Peterlongo et al,
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September 2010; published online 9 November 2010
*Correspondence: Dr SM Farrington;
E-mail: Susan.Farrington@hgu.mrc.ac.uk
18 Present address: Infectious Disease Epidemiology Unit, London School
of Hygiene and Tropical Medicine, Keppel Street, London, UK
British Journal of Cancer (2010) 103, 1875 – 1884
& 2010 Cancer Research UK All rights reserved 0007 – 0920/10
www.bjcancer.com
G
e
n
e
ti
c
s
a
n
d
G
e
n
o
m
ic
s
2005; Zhou et al, 2005; Moreno et al, 2006; Tenesa et al, 2006;
Webb et al, 2006; Ku¨ry et al, 2007; Cleary et al, 2009; Lubbe
et al, 2009). Although an increased CRC risk associated with
bi-allelic MUTYH mutations is incontrovertible, the risk associated
with one MUTYH mutant allele is controversial (Croitoru et al,
2004; Farrington et al, 2005; Jenkins et al, 2006; Tenesa et al,
2006; Webb et al, 2006; Cleary et al, 2009; Jones et al, 2009;
Lubbe et al, 2009). A statistically significant or close to significant
effect, for a MUTYH mono-allelic effect, has been reported in
different studies with possible age specific effects present, but the
rarity of the alleles associated with the small increased risk for CRC
have made it difficult to replicate study findings. A recent risk
analysis of MAP family members agreed with previous family
based findings (Jenkins et al, 2006) that mono-allelic carriers are at
a two-fold increase in risk of CRC (Jones et al, 2009) providing
further evidence of a mono-allelic effect of the gene. However,
family based studies can be subject to ascertainment bias and any
mono-allelic effect could potentially be modified by other inherited
factors, including alleles at other loci. Furthermore, environmental
risk factors also show familial aggregation and hence, studies in
which there has been selection of cases based on family history
may be confounded. Bi-allelic carriers may develop CRC because
of the predominant effect of MUTYH, whereas the environmental
effect is greater in affected siblings with mono-allelic mutations
but the risk is ascribed to the MUTYH allele. Thus further work is
required to resolve the mono-allelic carrier risk question.
To clarify the role of MUTYH in disease risk, we initiated a
multi-centre collaboration allowing large-scale meta-analysis of the
individual MUTYH variants, with special interest in determining if
there were age and sex-specific effects on CRC association with
MUTYH variants (Farrington et al, 2006). In this study, we present
the results of this collaborative meta-analysis.
SUBJECTS AND METHODS
Participating studies
Relevant case–control studies to be invited for inclusion in the
meta-analysis of the effect of MUTYH on CRC risk were identified
by a literature search in the ISI Web of Science (http://
wok.mimas.ac.uk) and PUBMED bibliographic databases (http://
www.ncbi.nlm.nih.gov/pubmed/), using the search terms ‘MYH or
MUTYH and CRC’. In the initial search 55 studies were identified
and eight of these were considered for our study (Enholm et al,
2003; Croitoru et al, 2004; Fleischmann et al, 2004; Kambara
et al, 2004; Wang et al, 2004; Farrington et al, 2005; Peterlongo
et al, 2005; Zhou et al, 2005). The inclusion criteria were as
follows: the patients had to be diagnosed with CRC and the studies
had to have genotype data for both cases and controls. Ten
additional studies were identified during the progress of the
project – Webb et al (2006), Moreno et al (2006), Ku¨ry et al (2007),
Cleary et al (2009), Lubbe et al (2009); and unpublished data from
Koessler T and Pharoah PD; and Tomlinson – personal commu-
nication. Colebatch et al (2006); Balaguer et al (2007); Avezzu`
et al (2008) were used in the pooled meta-analysis of all available
published and unpublished datasets.
The principal investigators (PIs) of the selected studies were
contacted and were asked to participate by providing a minimum
dataset including variables necessary for the analysis (Supplemen-
tary Box 1: Study questionnaire; Supplementary Table 1: Data
extraction table). In cases, in whom PIs failed to respond to our
invitation to participate, reminder letters were despatched. It was
not possible to include data from the following studies in the
logistic regression analyses because (i) data was only available for
cases that were heterozygous or homozygous for a MUTYH
mutation (Enholm et al, 2003); (ii) co-variate data were only
available for cases, as controls were anonymous blood donors
(Zhou et al, 2005; Tomlinson, unpublished data); (iii) failure to
communicate with us (Kambara et al, 2004 and Wang et al,
2004). The study by Fleischmann et al (2004) and Webb et al
(2006) were not used because they had been superseded by a later
study (Lubbe et al, 2009), which was included.
Statistical analysis
Data from all collaborating centres were checked for completeness,
coded and merged to form a core database. MUTYH defects were
considered pathogenic only if there was published evidence of
their pathogenicity. Individuals reported to have two defects of
MUTYH in the original report were classified as mutated/mutated
(MM), those with one defect as wild type/mutant (WM) and those
with no mutation as wild type/wild type (WW). Descriptive
statistics were produced on all subject characteristics, risk factors
and event data. All populations described in the case–control
studies were tested for Hardy– Weinberg equilibrium in controls
and the genotype distributions between all groups were compared
by w2-test.
Three logistic regression models were applied to address
confounding co-variates (model I: crude, model II: including
co-variates for age and sex, model III: including co-variates for
age, sex and study) on the combined datasets investigating the effect
of MUTYH defects (WM vs WW and MM vs WW) as well as of the
individual mutations Y179C (c.536A4G/p.Tyr179Cys; AA¼WW,
GG¼MM) and G396D (c.1187G4A/p.Gly396Asp; GG¼WW,
AA¼MM; previously known as Y165C and G382D), to identify
any variant specific associations. The three logistic regression
models were applied after sex and age (over 55 years and under or
equal 55 years) stratification as previously described (Farrington
et al, 2005), to assess the effect of age and sex on the association of
the variants with disease risk. In all the studies, interaction
associations between the MUTYH variants and study code (for
each individual study) were estimated and similarly between
MUTYH variants and hormone replacement therapy (HRT) among
female participants in three studies (the Scottish SOCCS studies
and the studies – Croitoru et al, 2004; Cleary et al, 2009).
Association between both genetic (i.e., one of the MUTYH
mutations) and the study code or environmental factor (i.e.,
HRT) and disease was assessed and interaction was tested by
fitting interactive and nested multiplicative models. To assess for
any small study effects, we performed Funnel plot analysis and
tested for significance using the Harbord test.
Finally, the relationship between the genotype and CRC was
analysed by meta-analysis, combining the effect estimates of all
published and unpublished datasets.
All statistic analyses were conducted using Intercooled STATA
version 10.0 (Stata Corp, College Station, TX, USA). For the logistic
regression analyses, it is necessary to add a whole number to any
fields containing 0 (see model Ia in Table 2), which reduces the
final OR value, however, by using the META command in the
STATA meta-analysis programme, a lower value can be added
(0.5 as indicated by model Ib in Table 2) thereby giving a more
accurate assessment of risk. However, this is a grouped analysis
and therefore cannot be adjusted for confounding co-variates, such
as age/sex and study as in models II and III. To account for
multiple testing we applied the Bonferroni correction method, and
the P-value threshold for significance was estimated to be 0.003.
RESULTS
Table 1 details summary data from the studies included in our
combined analysis (comprising a total of 20 565 cases and 15 524
controls). The two variant alleles are rare with G396D variant allele
having a frequency of 0.007 in controls and the Y179C variant
allele a frequency of 0.002. Tests for deviation from Hardy–
Weinberg equilibrium in controls were P¼ 0.99 and Po0.00005
for G396D and Y179C variants, respectively.
Collaborative MUTYH risk analysis
E Theodoratou et al
1876
British Journal of Cancer (2010) 103(12), 1875 – 1884 & 2010 Cancer Research UK
G
e
n
e
tic
s
a
n
d
G
e
n
o
m
ic
s
T
a
b
le
1
Su
m
m
ar
y
ta
b
le
a
G
3
9
6
D
Y
1
7
9
C
G
e
n
o
ty
p
e
A
g
e
S
e
x
E
th
n
ic
it
y
S
tu
d
y
N
u
m
b
e
r
G
G
G
A
A
A
A
A
A
G
G
G
W
W
W
M
M
M
n
(%
)
M
e
a
n
(S
D
)
n
(%
)
M
a
le
s
(%
)
n
(%
)
C
a
u
c
a
si
a
n
/W
h
it
e
(%
)
A
ll
st
ud
ie
s
C
as
es
2
0
5
6
5
1
9
9
6
6
3
2
4
3
3
2
0
2
6
0
1
5
4
1
1
1
9
7
8
3
4
1
7
7
6
2
0
5
5
5
(9
9
.9
)
5
9
.5
(1
0
.1
)
2
0
5
5
5
(9
9
.9
)
1
1
6
6
8
(5
6
.8
)
5
3
7
4
(2
6
.1
)
5
0
3
0
(9
3
.6
)
C
on
tr
ol
s
1
5
5
2
4
1
5
1
4
5
2
1
1
0
1
5
0
7
4
6
8
2
1
4
7
2
3
2
8
0
2
1
5
2
8
7
(9
8
.5
)
5
9
.0
(1
0
.9
)
1
5
5
2
1
(9
9
.9
)
6
8
4
5
(4
4
.1
)
5
5
9
7
(3
6
.1
)
4
7
9
6
(8
5
.7
)
C
ro
ito
ru
et
al
(2
0
0
4
)
C
as
es
1
2
3
8
1
2
0
9
2
5
4
1
2
2
3
1
3
2
1
1
9
7
2
9
1
2
1
2
3
6
(9
9
.8
)
6
0
.1
(8
.7
)
1
2
3
6
(9
9
.8
)
5
4
4
(4
4
.0
)
M
is
si
ng
M
is
si
ng
C
on
tr
ol
s
1
2
5
5
1
2
3
8
1
7
0
1
2
5
1
4
0
1
2
3
4
2
1
0
1
2
4
4
(9
9
.1
)
6
3
.6
(8
.6
)
1
2
5
2
(9
9
.8
)
7
0
2
(5
6
.1
)
M
is
si
ng
M
is
si
ng
P
et
er
lo
ng
o
et
al
(2
0
0
5
)
C
as
es
5
8
5
5
6
7
3
1
5
6
9
3
0
5
5
2
4
2
5
8
4
(9
9
.8
)
6
2
.1
(1
3
.1
)
5
8
4
(9
9
.8
)
3
1
9
(5
4
.6
)
5
8
5
(1
0
0
)
2
5
1
(4
2
.9
)
C
on
tr
ol
s
1
1
5
8
1
0
4
0
5
0
1
0
3
9
2
0
9
2
3
7
0
1
1
4
8
(9
9
.1
)
5
3
.9
(1
1
.5
)
1
1
5
6
(9
9
.8
)
2
4
0
(2
0
.8
)
1
1
5
8
(1
0
0
)
3
6
3
(3
1
.3
)
SO
C
C
S
(i
nc
lu
d
es
d
at
a
fr
o
m
Fa
rr
in
gt
o
n
et
al
(2
0
0
5
),
T
en
es
a
et
al
(2
0
0
6
)
an
d
un
p
ub
lis
he
d
SO
C
C
S
p
ro
sp
ec
tiv
e
sa
m
p
le
s)
C
as
es
3
2
7
8
3
0
8
6
5
5
8
3
1
9
2
2
3
0
3
0
3
8
7
1
1
2
3
2
7
7
(1
0
0
)
5
9
.5
(1
1
.3
)
3
2
7
8
(1
0
0
)
1
8
8
3
(5
7
.4
)
3
2
7
8
(1
0
0
)
3
2
6
8
(9
9
.7
)
C
on
tr
ol
s
3
3
1
8
3
2
3
9
4
3
0
3
0
6
1
1
5
0
2
9
9
3
5
7
0
3
3
1
3
(9
9
.8
)
6
1
.4
(1
0
.9
)
3
3
1
8
(1
0
0
)
1
8
6
1
(5
6
.1
)
3
3
1
8
(1
0
0
)
3
3
1
2
(9
9
.8
)
M
o
re
no
et
al
(2
0
0
6
)
C
as
es
3
5
6
3
4
3
8
1
3
4
8
0
0
3
3
6
8
1
3
5
6
(1
0
0
)
6
6
.5
(1
1
.7
)
3
5
6
(1
0
0
)
2
1
7
(6
1
.0
)
M
is
si
ng
M
is
si
ng
C
on
tr
ol
s
2
9
7
2
8
5
7
0
2
9
1
0
0
2
8
3
7
0
2
9
7
(1
0
0
)
6
5
.3
(1
2
.5
)
2
9
7
(1
0
0
)
1
5
8
(5
3
.2
)
M
is
si
ng
M
is
si
ng
K
o
es
sl
er
T
,
(u
np
ub
lis
he
d
d
at
a
o
b
ta
in
ed
in
2
0
0
7
)
C
as
es
2
2
6
2
2
2
1
5
3
1
2
2
2
2
7
1
9
1
2
1
9
8
3
7
9
2
2
5
3
(9
9
.6
)
5
9
.1
(8
.1
)
2
2
6
2
(1
0
0
)
1
2
8
7
(5
7
.1
)
M
is
si
ng
M
is
si
ng
C
on
tr
ol
s
2
2
5
3
2
2
1
7
3
1
0
2
2
3
6
1
1
0
2
2
0
4
4
2
0
2
0
5
3
(9
1
.1
)
5
3
.4
(7
.6
)
2
2
5
3
(1
0
0
)
9
4
9
(4
2
.0
)
M
is
si
ng
M
is
si
ng
K
u¨r
y
et
al
(2
0
0
7
)
C
as
es
1
0
2
5
1
0
0
3
2
2
0
1
0
2
1
4
0
9
9
9
2
5
1
1
0
2
3
(9
9
.8
)
6
8
.7
(9
.9
)
1
0
2
5
(1
0
0
)
6
3
2
(6
1
.7
)
1
0
2
5
(1
0
0
)
1
0
2
5
(1
0
0
)
C
on
tr
ol
s
1
1
2
1
1
1
0
5
1
6
0
1
1
1
7
4
0
1
1
0
0
2
1
0
1
1
2
1
(1
0
0
)
6
1
.9
(1
0
.0
)
1
1
2
1
(1
0
0
)
6
0
9
(5
4
.3
)
1
1
2
1
(1
0
0
)
1
1
2
1
(1
0
0
)
SO
C
C
S
re
tr
o
sp
ec
tiv
e
ca
se
s
(u
np
ub
lis
he
d
d
at
a
o
b
ta
in
ed
in
2
0
0
8
)
C
as
es
4
8
6
4
0
3
6
2
4
4
6
2
3
3
9
1
6
4
4
8
6
(1
0
0
)
5
4
.7
(1
7
.2
)
4
7
9
(9
8
.6
)
2
4
0
(5
0
.1
)
4
8
6
(1
0
0
)
4
8
6
(1
0
0
)
C
on
tr
ol
s
0
0
0
0
0
0
0
0
0
0
0
0
0
C
le
ar
y
et
al
(2
0
0
9
)
C
as
es
2
0
7
6
2
0
2
3
3
3
5
2
0
5
3
7
1
2
0
2
9
3
8
9
2
0
7
0
(9
9
.7
)
5
6
.6
(1
0
.8
)
2
0
7
6
(1
0
0
)
1
1
1
4
(5
3
.7
)
M
is
si
ng
M
is
si
ng
C
on
tr
ol
s
1
0
4
9
1
0
3
2
1
7
0
1
0
4
2
6
1
1
0
2
4
2
4
1
1
0
4
7
(9
9
.8
)
5
6
.4
(1
1
.3
)
1
0
4
9
(1
0
0
)
4
4
4
(4
2
.3
)
M
is
si
ng
M
is
si
ng
Lu
b
b
e
et
al
(2
0
0
9
)b
C
as
es
9
2
6
8
9
1
1
7
1
4
1
1
0
9
1
8
1
8
3
4
9
0
4
3
1
9
8
2
7
9
2
6
8
(1
0
0
)
5
9
.0
(8
.5
)
9
2
6
8
(1
0
0
)
5
4
3
2
(5
8
.6
)
M
is
si
ng
M
is
si
ng
c
C
on
tr
ol
s
5
0
6
4
4
9
8
9
7
5
0
5
0
3
7
2
6
1
4
9
6
2
1
0
1
1
5
0
6
4
(1
0
0
)
5
9
.2
(1
0
.8
)
5
0
6
4
(1
0
0
)
1
8
8
2
(3
7
.2
)
M
is
si
ng
M
is
si
ng
c
A
b
b
re
vi
at
io
ns
:
M
M
¼
m
ut
at
ed
/m
ut
at
ed
;
W
M
¼
w
ild
ty
p
e/
m
ut
an
t;
W
W
¼
w
ild
ty
p
e/
w
ild
ty
p
e.
a T
hi
s
ta
b
le
p
re
se
nt
s
th
e
ra
w
d
at
a
se
nt
to
us
b
y
ea
ch
gr
o
up
th
at
w
as
th
en
in
cl
ud
ed
in
th
e
an
al
ys
es
.
G
3
9
6
D
an
d
Y
1
7
9
C
ar
e
lo
o
ke
d
at
in
d
ep
en
d
en
tly
an
d
an
y
co
m
p
o
un
d
b
i-
al
le
lic
ca
rr
ie
rs
ar
e
p
re
se
nt
ed
as
he
te
ro
zy
go
te
s
fo
r
ea
ch
va
ri
an
t;
M
U
T
Y
H
ge
no
ty
p
e
d
at
a
al
so
in
cl
ud
es
o
th
er
p
at
ho
ge
ni
c
m
ut
at
io
ns
;u
np
ub
lis
he
d
d
at
a
ar
e
in
cl
ud
ed
in
P
et
er
lo
no
go
P
an
d
M
o
re
no
V
,
SO
C
C
S
p
ro
sp
ec
tiv
e
an
d
K
u¨r
y
S.
b
In
cl
ud
es
d
at
a
fr
o
m
W
eb
b
et
al
(2
0
0
6
)
an
d
Fl
ei
sc
hm
an
n
et
al
(2
0
0
4
).
c A
ll
th
e
ca
se
s
an
d
co
nt
ro
ls
w
er
e
U
K
re
si
d
en
ts
an
d
o
f
Eu
ro
p
ea
n
an
ce
st
ry
(s
el
f-
re
p
o
rt
ed
).
Collaborative MUTYH risk analysis
E Theodoratou et al
1877
British Journal of Cancer (2010) 103(12), 1875 – 1884& 2010 Cancer Research UK
G
e
n
e
ti
c
s
a
n
d
G
e
n
o
m
ic
s
Table 2 Logistic regression analysis of the combined datasets; G396D analysis was conducted for individuals that were Y179C AA; Y179C analysis was
conducted for individuals that were G396D GG; combined genotype analysis was conducted for individuals with data for both Y179C and G396D
Model I*,a Model Ib
Gene Cases Controls OR 95% CI P-value OR 95% CI P-value
G396Dc
Whole sample
GG 19 767 14 723 1.00
GA 292 210 1.04 0.87, 1.24 0.70
AA 31 0 23.09 3.15, 169.15 0.002 46.93 2.87, 766.89 0.007
p55 Years old
GG 6269 5270 1.00
GA 88 77 0.96 0.71, 1.31 0.80
AA 13 0 10.93 1.43, 83.57 0.02 22.70 1.35, 381.91 0.03
455 Years old
GG 13 498 9453 1.00
GA 204 133 1.07 0.86, 1.34 0.52
AA 18 0 12.60 1.68, 94.37 0.01 25.91 1.56, 430.03 0.02
Males
GG 11 229 6460 1.00
GA 161 95 0.98 0.76, 1.26 0.85
AA 15 0 8.62 1.14, 65.25 0.04 17.84 1.07, 298.11 0.04
Females
GG 8528 8259 1.00
GA 131 115 1.10 0.86, 1.42 0.45
AA 16 0 15.49 2.05, 116.86 0.008 31.96 1.92, 532.72 0.02
Y179Cd
Whole sample
AA 19 767 14 723 1.00
AG 122 68 1.34 1.00, 1.80 0.05
GG 11 2 4.10 0.91, 18.48 0.07 NA
p55 Years old
AA 6269 5270 1.00
AG 35 25 1.18 0.70, 1.97 0.54
GG 9 0 7.57 0.96, 59.74 0.06 15.97 0.93, 274.491 0.06
455 Years old
AA 13 498 9453 1.00
AG 87 43 1.42 0.98, 2.04 0.06
GG 2 2 0.70 0.10, 4.97 0.72 NA
Males
AA 11 229 6460 1.00
AG 68 23 1.70 1.06, 2.73 0.03
GG 8 0 4.60 0.58, 36.80 0.15 9.78 0.56, 169.48 0.12
Females
AA 8528 8259 1.00
AG 54 45 1.16 0.78, 1.73 0.46
GG 3 2 1.45 0.24, 8.70 0.68 NA
Genotypee
Whole sample
WW 19767 14 723 1.00
WM 418 280 1.11 0.95, 1.29 0.17
MM 76 2 28.30 6.95, 115.26 3.1 106 NA
G396D AA 31 0 23.09 3.15, 169.15 0.002 46.93 2.87, 766.89 0.007
Y179C GG 11 2 4.10 0.91, 18.48 0.07 NA
Compound heterozygousf 29 0 21.60 2.94, 158.58 0.003 43.95 2.69, 719.26 0.008
p55 Years old
WW 6269 5270 1.00
WM 124 104 1.00 0.77, 1.30 0.99
MM 43 0 36.15 4.98, 262.57 0.0004 73.14 4.50, 1188.3 0.003
G396D AA 13 0 10.93 1.43, 83.57 0.02 22.70 1.35, 381.91 0.03
Y179C GG 9 0 7.57 0.96, 59.74 0.06 15.97 0.93, 274.49 0.06
Compound heterozygous 17 0 14.29 1.90, 107.42 0.01 29.42 1.77, 489.38 0.02
455 Years old
WW 13498 9453 1.00
WM 294 176 1.17 0.97, 1.41 0.10
MM 33 2 11.56 2.77, 48.17 0.001 NA
G396D AA 18 0 12.60 1.68, 94.37 0.01 25.91 1.56, 430.03 0.02
Y179C GG 2 2 0.70 0.10, 4.97 0.72 NA
Compound heterozygous 12 0 8.40 1.09, 64.64 0.04 17.51 1.04, 295.75 0.05
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Bi-allelic effect of MUTYH
All three models of the logistic regression analysis gave consistent
results and so the results of the crude analysis (model I) are
described below and presented in Table 2; results of the other two
models can be found in Supplementary Table 2. Bi-allelic carriers
for the MM genotype of the combined MUTYH defects, G396D
and Y179C/G396D compound heterozygotes were associated with
a significant increase in CRC risk (odds ratio (OR)¼ 28.3,
95% confidence limits (CIs): 6.95–115; 23.1 (95% CI: 3.15–169)
and 21.6 (95% CI: 2.94–159), respectively). These risks are
conservative, concentrating on the significant logistic regression
results – model Ib results presented in Table 2 are likely a better
reflection of risk and tend to be two-fold higher. There was a greater
CRC risk for the MM genotype for the earlier age individuals when
compared with the older age group (OR¼ 36.2 (95% CI: 4.98–263)
forp55 years compared with 11.6 (95% CI: 2.77–48.2) for455 years).
However, their CIs overlapped and the results were not statistically
significantly different. ANOVA analysis of mean age of carriers
demonstrated that there are significant age differences between
cases and controls when considering MM genotype carriers and
Y179C bi-allelic carriers but not for G396D carriers (Po0.0005,
Po0.0005 and P¼ 0.27, respectively – Supplementary Table 3).
Indeed there is a significant age difference between mean age of
bi-allelic Y179C and G396D carriers (48.9 vs 56.7, respectively,
P¼ 0.003 based on t-test – Supplementary Table 4).
Colorectal cancer risk associated with mono-allelic
MUTYH mutations
The results of the combined analysis demonstrate that there are no
significant mono-allelic effects for either G396D or for combined
MUTYH variants (Table 2). However, the specific Y179C variant
was shown to increase risk of disease in the heterozygous
state (OR¼ 1.34; (95% CI: 1.00–1.80)) in the whole sample
set and also when stratified by sex, male sex demonstrated a
mono-allelic effect (OR¼ 1.70; (95% CI: 1.06–2.73)). However,
after Bonferroni correction, these mono-allelic effects did not
remain significant.
The role of study population and HRT in modulating
CRC risk
We hypothesised that origin of the data, that is, study population
might modify the association between the genotype and CRC
risk. However, there was no evidence for an interaction between
study code and MUTYH genotypes (Supplementary Table 5).
Similarly, HRT intake, a known risk factor for CRC (Chan et al,
2006; Theodoratou et al, 2008), might be influenced by genotype
and therefore modulate female risk. Both the Scottish and
Canadian datasets had recorded data on HRT intake and these
were used to test for an interaction between HRT and MUTYH
genotype. Across both datasets there was no evidence of any
interaction between HRT and MUTYH genotype (Supplementary
Table 6).
Meta-analysis of published and unpublished datasets
The results of a meta-analysis of published and unpublished
datasets submitted to us, estimating the effect of the MUTYH
whole gene defects demonstrated a pooled fixed bi-allelic effect of
10.8 (95% CI: 5.02– 23.2) for the MM and a pooled fixed mono-
allelic effect of 1.16 (95% CI: 1.00– 1.34) for WM genotype (Table 3;
Figures 1 and 2). Analysis of the specific variants by pooled
meta-analysis demonstrated bi-allelic effects for both G396D and
Y179C (OR¼ 6.47 (95% CI: 2.33–18.0) and OR¼ 3.35 (95% CI:
1.14– 9.89), respectively) and in agreement with the logistic
regression analysis results, Y179C variant also demonstrated
a very similar pooled fixed mono-allelic effect of 1.34 (95%
CI: 1.01–1.77; Tables 4 and 5; Supplementary Figures 1 –4).
Assessment of study publication bias
Funnel plots for both the mono- and bi-allelic effect were created
to assess whether study size was significantly influencing the
results. These plots appeared asymmetric, but the Harbord’s test
for small study effect demonstrated that this was not statistically
significant (Supplementary Figures 5 and 6).
Table 2 (Continued )
Model I*,a Model Ib
Gene Cases Controls OR 95% CI P-value OR 95% CI P-value
Males
WW 11229 6460 1.00
WM 232 119 1.12 0.90, 1.40 0.31
MM 36 0 20.71 2.84, 151.09 0.003 42.00 2.58, 684.38 0.009
G396D AA 15 0 8.62 1.14, 65.25 0.04 17.84 1.07, 298.11 0.04
Y179C GG 8 0 4.60 0.58, 36.80 0.15 9.78 0.56, 169.48 0.12
Compound heterozygous 12 0 6.90 0.90, 53.10 0.06 14.38 0.85, 242.96 0.06
Females
WW 8528 8259 1.00
WM 186 161 1.12 0.90, 1.38 0.30
MM 40 2 19.37 4.68, 80.17 4.3 105 NA
G396D AA 16 0 15.49 2.05, 116.86 0.008 31.96 1.92, 532.72 0.02
Y179C GG 3 2 1.45 0.24, 8.70 0.68 NA
Compound heterozygous 17 0 16.46 2.19, 123.70 0.006 33.90 2.04, 563.74 0.01
Abbreviations: CI¼ confidence interval; MM¼mutated/mutated; NA¼ not available; OR¼ odds ratio; WM¼wild type/mutant; WW¼wild type/wild type. *Crude analysis.
aEstimated by adding one control with the variant genotype. bEstimated using the meta command of STATA and for mathematical reasons, cells with zero frequencies were
assumed to be 0.5 (as defaulted by the meta command). cAnalysis conducted only for the AA Y179C, that is, WW. dAnalysis conducted only for the GG G396D, that is, WW.
eIncluding subjects with data for both Y179C and G396D. fThis category includes 29 G396D GA and Y179C AG cases; 5 cases with either G396D GA or Y179C AG and any
other pathogenic MUTYH mutation were excluded.
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DISCUSSION
This large meta-analysis study refines the estimates of CRC risk
associated with mutations in the MUTYH gene to date. Bi-allelic
carriers of the combined MUTYH mutations (MM) are associated
with a 28-fold (95% CI: 6.95–115) increase in CRC risk from the
logistic regression analysis. Bi-allelic carriers of the G396D variant
and Y179C/G396D compound heterozygotes were also significantly
associated with a similar increase in CRC risk (OR¼ 23.1 (95% CI:
3.15– 169) and 21.6 (95% CI: 2.94–159), respectively). Although
the risk estimate was slightly lower from the overall larger pooled
meta-analysis of published and unpublished datasets (OR¼ 10.8
Table 3 Meta-analysis of studiesa
Genotype (cases) Genotype (controls)
WM vs WW MM vs WW
Study WW WM MM WW WM MM OR (95% CI) OR (95% CI)
Enholm et al (2003) 994 5 4 424 0 0 4.70 (0.26, 85.10) 3.84 (0.21, 71.51)
Kambara et al (2004) 90 2 0 52 — 0 1.16 (0.10, 13.06) NA
Wang et al (2004) 432 10 2 309 4 0 1.79 (0.56, 5.75) 3.58 (0.17, 74.79)
Zhou et al (2005) 432 6 0 466 3 0 2.16 (0.54, 8.68) NA
Peterlongo et al (2005) 549 4 2 911 7 0 0.95 (0.28, 3.25) 8.29 (0.40, 173.08)
Tomlinson I (2006)b 662 15 1 197 2 0 2.23 (0.51, 9.84) 0.89 (0.04, 22.04)
Moreno et al (2006) 323 9 0 278 6 0 1.29 (0.45, 3.67) NA
Colebatch et al (2006) 859 11 2 473 5 0 1.21 (0.42, 3.51) 2.75 (0.13, 57.49)
Koessler T (2007)c 2198 37 9 2204 42 0 0.88 (0.57, 1.38) 19.05 (1.11, 327.53)
Ku¨ry et al (2007) 999 24 1 1100 21 0 1.26 (0.70, 2.27) 3.30 (0.13, 81.18)
Balaguer et al (2007) 1089 19 8 912 22 0 0.72 (0.39, 1.34) 14.24 (0.82, 247.02)
SOCCS (2008)d 3429 77 16 2993 57 0 1.18 (0.83, 1.67) 28.80 (1.73, 480.32)
Avezzu` et al (2008) 435 2 2 246 1 0 1.13 (0.10, 12.54) 2.83 (0.14, 59.19)
Cleary et al (2009)e 3697 87 27 2758 43 1 1.51 (1.04, 2.18) 20.14 (2.74, 148.32)
Lubbe et al (2009)f 9043 198 27 4962 101 1 1.08 (0.84, 1.37) 14.82 (2.01, 109.06)
M–H pooled effect (fixed) 25231 506 101 18285 315 2 1.16 (1.00, 1.34) 10.80 (5.02, 23.21)
P-value 0.05 o0.0005
Heterogeneity
P-value 0.82 0.84
I2 (95% CI) 0 (0, 54) 0 (0, 60)
Abbreviations: CI¼ confidence interval; MM¼mutated/mutated; NA¼ not available; OR¼ odds ratio; WM¼wild type/mutant; WW¼wild type/wild type. aThis table presents
the data as they were published. Two unpublished studies included. bUnpublished data obtained in 2006. cUnpublished data obtained in 2007. dIncludes data from Farrington et al
(2005), Tenesa et al (2006) and unpublished data from the SOCCS study obtained in 2008. eIncludes data from Croitoru et al (2004). fIncludes data fromWebb et al (2006) and
Fleischmann et al (2004).
Overall  (I 2 = 0.0%, P = 0.837)
Avezzu et al (2008)
Kossler T (2007)
Tomlinson I (2006)
Moreno et al (2006)
Zhou et al (2004)
Kambara et al (2004)
Balaguer et al (2007)
Lubbe et al (2009)
Küry S et al (2007)
Enholm et al (2003)
Cleary et al (2008)
Wang et al (2004)
Colebatch et al (2006)
Peterlongo et al (2005)
SOCCS (2008)
Study
ID
10.80 (5.02, 23.21)
2.83 (0.14, 59.19)
19.05 (1.11, 327.53)
0.89 (0.04, 22.04)
(Excluded)
(Excluded)
(Excluded)
OR (95% CI)
14.24 (0.82, 247.02)
14.82 (2.01, 109.06)
3.30 (0.13, 81.18)
3.84 (0.21, 71.51)
20.14 (2.74, 148.32)
3.58 (0.17, 74.79)
2.75 (0.13, 57.49)
8.29 (0.40, 173.08)
28.80 (1.73, 480.32)
100.00
7.77
6.09
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0.00
0.00
6.62
15.76
5.81
8.54
13.94
7.10
7.87
4.59
6.51
Weight (%)
10.1 10
Figure 1 Meta-analysis of studies comparing MUTYH MM vs WW. SOCCS data include Farrington et al (2005), Tenesa et al (2006) and unpublished data
from the SOCCS study obtained in 2008; Cleary data include Croitoru et al (2004); Lubbe data include Webb et al (2006) and Fleischmann et al (2004).
Unpublished studies included are Tomilson I (2006) and Koessler T (2007).
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(95% CI: 5.02–23.2)), both G396D and Y179C variants demon-
strated bi-allelic effects in this pooled analysis (OR¼ 6.47 (95% CI:
2.33– 18.0) and OR¼ 3.35 (95% CI: 1.14–9.89), respectively).
A marginal significant mono-allelic effect was demonstrated for the
specific variant Y179C (OR¼ 1.34 (95% CI: 1.00–1.80)) and indeed
a marginally significant result was also observed in the pooled
meta-analysis for MUTYH WM (OR¼ 1.16 (95% CI: 1.00–1.34))
and Y179C variant alone, 1.34 (95% CI: 1.01– 1.77). The increased
bi-allelic risk of CRC varied when stratified for age and sex but
none of the differences were significant, although when stratified
by sex, males showed a marginal significant mono-allelic effect for
Y179C (OR¼ 1.70; 95% CI: 1.06– 2.73). The results from this large
dataset indicate that the two variants may be acting mecha-
nistically differently; G396D appears to be a true example of
Overall  (I2 = 0.0%, P = 0.821)
Moreno et al (2006)
Zhou et al (2005)
Avezzu et al (2008)
Kambara et al (2004)
Balaguer et al (2007)
Study
ID
Enholm et al (2003)
SOCCS (2008)
Colebatch et al (2006)
Wang et al (2004)
Cleary et al (2008)
Peterlongo et al (2005)
Tomlinson I (2006)
Lubbe et al (2009)
1.16 (1.00, 1.34)
1.29 (0.45, 3.67)
2.16 (0.54, 8.68)
1.13 (0.10, 12.54)
1.16 (0.10, 13.06)
0.72 (0.39, 1.34)
1.26 (0.70, 2.27)
4.70 (0.26, 85.10)
1.18 (0.83, 1.67)
1.21 (0.42, 3.51)
1.79 (0.56, 5.75)
0.88 (0.57, 1.38)
OR (95% CI)
1.51 (1.04, 2.18)
0.95 (0.28, 3.25)
2.23 (0.51, 9.84)
1.08 (0.84, 1.37)
100.00
1.79
0.81
0.36
0.35
6.68
Weight (%)
5.57
0.20
16.97
1.81
1.30
11.73
13.74
1.49
0.86
36.34
10.1 10
Küry S et al (2007)
Koessler T (2007)
Figure 2 Meta-analysis of studies comparing MUTYH WM vsWW. SOCCS data include Farrington et al (2005), Tenesa et al (2006) and unpublished data
from the SOCCS study obtained in 2008; Cleary data include Croitoru et al (2004); Lubbe data include Webb et al (2006) and Fleischmann et al (2004).
Unpublished studies included are Tomilson I (2006) and Koessler T (2007).
Table 4 Meta-analysis of studies for the G396D genotypesa
G396D (cases) G396D (controls)
GA vs GG AA vs GG
Study GG GA AA GG GA AA OR (95% CI) OR (95% CI)
Enholm et al (2003) 994 4 1 424 0 0 3.84 (0.21, 71.51) 1.28 (0.05, 31.50)
Kambara et al (2004) 90 2 0 52 — 0 Not enough data available NA
Wang et al (2004) 432 5 0 309 2 0 1.79 (0.35, 9.28) NA
Zhou et al (2005) 432 1 0 466 1 0 1.08 (0.07, 17.30) NA
Peterlongo et al (2005) 549 2 0 911 5 0 0.66 (0.13, 3.43) NA
Tomlinson I (2006)b 662 9 1 197 2 0 1.34 (0.29, 6.25) 0.89 (0.04, 22.04)
Moreno et al (2006) 323 9 0 278 6 0 1.29 (0.45, 3.67) NA
Colebatch et al (2006) 859 8 0 473 4 0 1.10 (0.33, 3.67) NA
Koessler T (2007)c 2198 25 2 2204 31 0 0.81 (0.48, 1.37) 5.01 (0.24, 104.49)
Ku¨ry et al (2007) 999 21 0 1100 16 0 1.45 (0.75, 2.79) NA
Balaguer et al (2007) 1089 15 1 912 20 0 0.63 (0.32, 1.23) 2.51 (0.10, 61.75)
SOCCS (2008)d 3429 56 8 2993 42 0 1.16 (0.78, 1.74) 14.84 (0.86, 257.19)
Avezzu` et al (2008) 435 2 1 246 0 0 2.83 (0.14, 59.19) 1.70 (0.07, 41.84)
Cleary et al (2009)e 3697 63 11 2758 32 0 1.47 (0.96, 2.25) 17.16 (1.01, 291.31)
Lubbe et al (2009)f 9043 128 10 4962 75 0 0.94 (0.70, 1.25) 11.52 (0.68, 196.69)
M–H pooled effect (fixed) 25 231 350 35 18 285 236 0 1.07 (0.90, 1.26) 6.47 (2.33, 17.97)
P-value 0.44 o0.0005
Heterogeneity
P-value 0.74 0.73
I2 (95% CI) 0 (0, 55) 0 (0, 68)
Abbreviations: CI¼ confidence interval; MM¼mutated/mutated; NA¼ not available; OR¼ odds ratio; WM¼wild type/mutant; WW¼wild type/wild type. aThis table presents
the data as they were published. Two unpublished studies included. bUnpublished data obtained in 2006. cUnpublished data obtained in 2007. dIncludes data from Farrington et al
(2005), Tenesa et al (2006) and unpublished data from the SOCCS study obtained in 2008. eIncludes data from Croitoru et al (2004). fIncludes data from Webb et al (2006) and
Fleischmann et al (2004).
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recessive Mendelian disease, whereas the results for Y179C are
more complex and there is therefore some argument against
combining the two variants. However, the results from the Y179C/
G396D compound heterozygotes analysis demonstrates an increase
in risk similar to G396D bi-allelic carriers, suggesting that the two
variants are complementary and analysis of combined MUTYH
mutations as historically performed, appears appropriate to assess
risk for the whole gene. The rarity of the Y179C allele has made it
difficult to truly assess its effect on disease risk, however the large
numbers analysed in this report have resulted in the demonstra-
tion that both bi-allelic and mono-allelic Y179C variants are
associated with disease risk.
The study population did not appear to modulate disease risk
and although the study replicated the reported decrease in disease
risk in MUTYH wild-type females associated with HRT intake
(Chan et al, 2006; Theodoratou et al, 2008), we found no
interaction with the MUTYH gene and its variants. Therefore, it
is unlikely that HRT intake is an explanation for any sex variation
in risk and other genetic factors may be involved in modifying
CRC risk.
Evidence of a mono-allelic MUTYH effect on CRC has been
reported in several case–control studies (Croitoru et al, 2004;
Wang et al, 2004; Farrington et al, 2005; Zhou et al, 2005;
Tenesa et al, 2006; Cleary et al, 2009) and family-based studies
(Jenkins et al, 2006; Jones et al, 2009), but not in other studies
(Kambara et al, 2004; Webb et al, 2006; Balaguer et al, 2007;
Lubbe et al, 2009). Our large meta-analysis has demonstrated a
marginal significant association for the specific variant Y179C,
highlighting the possible increased phenotypic severity of this allele.
This is in agreement with other studies and biochemical and model
organism studies, which indicate that this variant shows an increased
detrimental effect on protein function (Al-Tassan et al, 2002;
Parker et al, 2005; Lubbe et al, 2009; Nielsen et al, 2009;
D’Agostino et al, 2010). The pooled analysis of published studies
and unpublished datasets submitted to us also indicated
a marginally significant mono-allelic MUTYH effect, as well as a
mono-allelic Y179C effect.
However, there are a number of caveats that need to be
considered; if any of the studied datasets contain cases recruited
because of the familial clustering of disease, there may be
ascertainment bias, artificially inflating the number of MUTYH
WM variant allele carriers; secondly the screening of the MUTYH
gene has predominantly been performed on the two most common
pathogenic variants Y179C and G396D – in some studies, the rest
of the gene may be explored in cases with a heterozygous allele for
these variants but not usually in the controls, hence there is an
overall screening bias and bi-allelic carriers may well have been
missed in both cases and controls.
The demonstration of a mono-allelic effect specifically for
Y179C should be considered with further caution, as analysis of the
control datasets for the Y179C allele demonstrated that it was not
in Hardy–Weinberg equilibrium. This may be because of several
factors, the rarity of the allele and the fact that both female control
subjects with bi-allelic mutations carry Y179C variants. One of
these control subjects was shown to have polyps on colonoscopy
(Cleary et al, 2009) and may therefore be considered a case. The
other is relatively young, less than 60 years old (Lubbe et al, 2009),
so potentially may develop cancer over the next few years.
However, in this large dataset, we have also shown that bi-allelic
carriers of Y179C predisposes to an earlier onset of disease than
G396D, consistent with previous reports (Lubbe et al, 2009;
Nielsen et al, 2009) and highlights a severer disease phenotype of
this variant.
In conclusion, inactivation of the MUTYH gene is a recessive
risk factor for CRC, with possible modifying effects indicated by
increased risk in cases with early age of onset, although not
significantly different in the current dataset. An increased risk
associated with mono-allelic MUTYH mutation is indicated, albeit
small and not currently clinically relevant, and likely specific for
the variant Y179C. Despite the size of this study it has not been
possible to definitively establish whether there are significant age
and sex effects of increasing disease risk for G396D and Y179C
carriers. The evidence presented raises the possibility of a mono-
allelic effect for Y179C, but the effect is low (OR 1.34; 95% CI:
Table 5 Meta-analysis of studies for the Y179C genotypesa
Y179C (cases) Y179C (controls)
AG vs AA GG vs AA
Study AA AG GG AA AG GG OR (95% CI) OR (95% CI)
Enholm et al (2003) 994 1 0 424 0 0 1.28 (0.05, 31.50) NA
Kambara et al (2004) 90 0 0 52 — 0 Not enough data available NA
Wang et al (2004) 432 5 1 309 2 0 1.79 (0.35, 9.28) 2.15 (0.09, 52.87)
Zhou et al (2005) 432 3 0 466 2 0 1.62 (0.35, 9.28) NA
Peterlongo et al (2005) 549 2 0 911 2 0 1.66 (0.23, 11.81) NA
Tomlinson I (2006)b 662 6 0 197 0 0 3.88 (0.22, 69.10) NA
Moreno et al (2006) 323 0 0 278 0 0 NA NA
Colebatch et al (2006) 859 3 0 473 1 0 1.65 (0.17, 15.93) NA
Koessler T (2007)c 2198 12 1 2204 11 0 1.09 (0.48, 2.48) 3.01 (0.12, 73.88)
Ku¨ry et al (2007) 999 3 0 1100 4 0 0.83 (0.18, 3.70) NA
Balaguer et al (2007) 1089 4 2 912 1 0 3.35 (0.37, 30.02) 4.19 (0.20, 87.34)
SOCCS (2008)d 3429 21 3 2993 15 0 1.22 (0.63, 2.38) 6.11 (0.32, 118.34)
Avezzu` et al (2008) 435 0 0 246 1 0 0.19 (0.01, 4.65) NA
Cleary et al (2009)e 3697 15 5 2758 10 1 1.12 (0.50, 2.50) 3.73 (0.44, 31.95)
Lubbe et al (2009)f 9043 70 4 4962 26 1 1.48 (0.94, 2.32) 2.20 (0.25, 19.64)
M-H pooled effect (fixed) 25 231 145 16 18 285 75 2 1.34 (1.01, 1.77) 3.35 (1.14, 9.89)
P-value 0.04 0.03
Heterogeneity
P-value 0.98 0.99
I2 (95% CI) 0 (0, 57) 0 (0, 75)
Abbreviations: CI¼ confidence interval; MM¼mutated/mutated; NA¼ not available; OR¼ odds ratio; WM¼wild type/mutant; WW¼wild type/wild type. aThis table presents
the data as they were published. Two unpublished studies included. bUnpublished data obtained in 2006. cUnpublished data obtained in 2007. dIncludes data from Farrington et al
(2005), Tenesa et al (2006) and unpublished data from the SOCCS study obtained in 2008. eIncludes data from Croitoru et al (2004). fIncludes data fromWebb et al (2006) and
Fleischmann et al (2004).
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1.00– 1.80) and is sensitive to variations in population allele
frequency because of the rarity of the variant (allele frequency
0.002), as well as potential issues of subgroup analysis and multiple
testing (indeed the overall significance is lost after Bonferoni
correction). Nonetheless, it does appear that this study is the first
to demonstrate that the Y179C variant does impart an increased
risk of CRC.
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